Authors of Large Meta-Analysis Predict End of KIF6 Test, but Celera Calls Study Flawed
October 13, 2010
Authors of Large Meta-Analysis Predict End of KIF6 Test, but Celera Calls Study Flawed
"Going forward, the KIF6 story should serve as a valuable reminder of the potential pitfalls present in prematurely adopting a genomic test without sufficient evidence," according to an editorial accompanying the study.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Future of Celera's KIF6 Test Unclear Amid FDA Rejection, Pending Quest Acquisition
April 27, 2011 / Pharmacogenomics Reporter - Medco Study Suggests Genetic Testing Improves Patient Compliance with Statins
October 19, 2011 / Pharmacogenomics Reporter - Celera Files for FDA OK for KIF6 Test
January 3, 2011 / GenomeWeb Daily News - Celera Licenses Decode Gene Markers to Grow Cardiovascular Dx Franchise
April 29, 2009 / Pharmacogenomics Reporter - With $10M in Funding and New Distribution Pact, Aviir Rolls out Protein Test for Cardiac Risk
March 1, 2013 / ProteoMonitor